Check for updates

#### OPEN ACCESS

EDITED BY Qi Zhao, University of Science and Technology Liaoning, China

#### REVIEWED BY Zhiwei Feng, University of Pittsburgh, United States Xing Chen, China University of Mining and Technology, China

\*CORRESPONDENCE Shan Chang [schang@jsut.edu.cn](mailto:schang@jsut.edu.cn) Ren Kong [rkong@jsut.edu.cn](mailto:rkong@jsut.edu.cn)

†These authors have contributed equally to this work

RECEIVED 21 March 2023 ACCEPTED 13 April 2023 PUBLISHED 12 May 2023

#### CITATION

Hu S, Yang G, Chen Z, Li Q, Liu B, Liu M, Zhang D, Chang S and Kong R (2023) Docking guided phase display to develop fusion protein with novel scFv and alkaline phosphatase for one-step ELISA salbutamol detection. *Front. Microbiol.* 14:1190793. doi: [10.3389/fmicb.2023.1190793](https://doi.org/10.3389/fmicb.2023.1190793)

#### COPYRIGHT

© 2023 Hu, Yang, Chen, Li, Liu, Liu, Zhang, Chang and Kong. This is an open-access article distributed under the terms of the [Creative](http://creativecommons.org/licenses/by/4.0/) [Commons Attribution License \(CC BY\).](http://creativecommons.org/licenses/by/4.0/) The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Docking guided phase display to develop fusion protein with novel [scFv and alkaline phosphatase for](https://www.frontiersin.org/articles/10.3389/fmicb.2023.1190793/full) one-step ELISA salbutamol detection

# Shuai Hu $^{1\dagger}$ , Guangbo Yang $^{1\dagger}$ , Zhou Chen $^1$ , Qiuye Li $^1$ , Bin Liu $^2$ , Ming Liu<sup>2</sup>, Dawei Zhang<sup>1</sup>, Shan Chang<sup>1\*</sup> and Ren Kong<sup>1\*</sup>

1 Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, School of Chemical and Environmental Engineering, Jiangsu University of Technology, Changzhou, China, <sup>2</sup>Beijing New BioConcepts Biotech Co., Ltd., Beijing, China

Introduction: Salbutamol (SAL) is a  $β2$  adrenergic receptor agonist which has potential hazardous effects for human health. It is very important to establish a sensitive and convenient method to monitor SAL.

Methods: Here we introduce a method to combine the information from docking and site specific phage display, with the aim to obtain scFv with high affinity to SAL. First, single chain variable fragment (scFv) antibodies against SAL were generated through phage display. By using molecular docking approach, the complex structure of SAL with antibody was predicted and indicated that H3 and L3 contribute to the binding. Then new libraries were created by randomization specific residues located on H3 and L3 according to the docking results.

Results and discussion: Anti-SAL scFv antibodies with high efficiency were finally identified. In addition, the selected scFv was fused with alkaline phosphatase and expressed in *E coli* to develop a rapid and low-cost one step ELISA to detect SAL.

#### KEYWORDS

phage display, docking, salbutamol, scFv, ELISA

# 1. Introduction

Salbutamol (SAL) is a β2 adrenergic receptor agonist, which is widely used to treat bronchial asthma [\(Price and Clissold, 1989\)](#page-8-0). Meanwhile, it can promote protein synthesis, increase animal lean meat rate, and improve feed conversion rate. It is often illegally used as a feed additive in animal husbandry [\(Baker et al., 1984;](#page-8-1) [Dalrymple et al., 1984;](#page-8-2) Jones et al., [1985\)](#page-8-3). Excessive intake of SAL can cause myalgia, headache, dizziness, nervousness, tachycardia, nausea, vomiting, and even cause liver and kidney damage, and its residues pose a serious hazard to human health [\(Wang and Shen, 2007;](#page-8-4) [Khamta et al., 2009;](#page-8-5) Sheu et al., [2009\)](#page-8-6). Therefore, SAL has been strictly banned as a feed additive by many countries, but due to its economic incentives, many farms still use SAL extensively [\(Kearns et al., 1985;](#page-8-7) [Garssen et al., 1995\)](#page-8-8). Illegal addition of SAL can cause environmental pollution and affect public health via the food chain [\(Wang et al., 2015\)](#page-8-9). Studies have shown that SAL has the possibility of entering the ecological environment through animal feces and urine. While causing environmental pollution, it then enters the human body through indirect channels [\(Fang et al., 2019\)](#page-8-10). SAL has already been a widespread environmental pollutant (Depaolini et al., [2016\)](#page-8-11). At present, SAL residues have been found in natural waters around the world, including tap water, wastewater, treated sewage, and river water [\(Yamini et al., 2006;](#page-9-0) Lei et al., [2015a\)](#page-8-12). Although the concentration of SAL in some water bodies has reached 470 ng/L



[\(Bound and Voulvoulis, 2006\)](#page-8-13), there are few reports focusing on environmental problems caused by SAL [\(Liu et al., 2018\)](#page-8-14). Therefore, it is imperative to establish a sensitive method to monitor SAL.

The analytical methods currently used to detect SAL include gas chromatography–mass spectrometry (GC-MS) (Black and Hansson, [1999\)](#page-8-15), high-performance liquid chromatography (HPLC) [\(Rosales-Conrado et al., 2013\)](#page-8-16), and high-performance liquid chromatography–mass spectrometry (HPLC-MS) (Zhang et al., [2012\)](#page-9-1). Because these methods require cumbersome sample preparation before instrumental analysis (Liu Z. J. et al., [2016\)](#page-8-17), it is difficult to meet the requirements for high-throughput and rapid screening of a large number of environmental samples. Immunoassay is a fast, low-cost, and high-throughput method, and it is becoming a reliable tool for the analysis of environmental pollutant residues. So far, many immunoassays for detecting SAL have been successfully developed. Among them, ELISA is the commonly used method for SAL detection [\(Degand et al., 1993;](#page-8-18) [Lei et al., 2008,](#page-8-19) [2015b\)](#page-8-20). Chemiluminescence and electrochemiluminescence assay, time-resolved immunofluorescence technique, and lateral chromatography technique (colloidal gold) have been developed for SAL and other β-agonist detection [\(Cai et al., 2015;](#page-8-21) [Xu et al.,](#page-8-22) [2015,](#page-8-22) [2022;](#page-8-23) [Liu B. et al., 2016;](#page-8-24) [Li et al., 2017;](#page-8-25) [Gu et al., 2020\)](#page-8-26).

Immunoassay methods also have some problems. For example, most of the currently available anti-SAL antibodies are polyclonal antibodies from sheep and rabbits [\(Degand et al., 1993;](#page-8-18) [Lei et al.,](#page-8-19) [2008;](#page-8-19) [Wu et al., 2014\)](#page-8-27), and their specificity is usually poor. For polyclonal antibodies, the heterogeneity of antibody preparations usually leads to cross-reactions with highly similar antigens. For example, polyclonal anti-SAL antibody shows significant cross-

reactivity to clenbuterol [\(Degand et al., 1993;](#page-8-18) [Lei et al., 2008;](#page-8-19) Wu et al., [2014\)](#page-8-27). Compared with polyclonal antibodies, monoclonal antibodies have the advantages of high specificity, and a relatively simple production process has been widely used in immunoassays. Adam et al. obtained an anti-salbutamol antibody by immunizing mice in 1990 and used the antibody to develop a radioimmunoassay for detecting salbutamol [\(Adam et al., 1990\)](#page-8-28). [Xie et al.](#page-8-29) [\(2012\)](#page-8-29) developed a new monoclonal anti-SAL antibody with improved affinity. Monoclonal antibodies have some disadvantages when applied in an immunoassay, such as high cost and long production cycle. ScFv antibodies can be expressed using *Escherichia coli*, effectively addressing the abovementioned issues. A chicken scFv anti-SAL has also been isolated and characterized by [Lee et al.](#page-8-30) [\(2018\)](#page-8-30). However, the initial affinity of these antibodies is typically too low for further application. High affinity and selectivity are critical issues for detecting ability so it is necessary to improve the affinity of antibodies derived from phage libraries.

Since antibodies still play a key role in immunoassays, the use of high-affinity antibodies could significantly improve the level of detection. Here, we have obtained anti-SAL scFvs from a rationally designed synthetic antibody library and improved its binding capacity with SAL through affinity maturation. In particular, the scFv binding site for SAL was predicted by molecular docking, and then, point mutation libraries were constructed based on the predicted results, which were used for antibody affinity maturation [\(Graphical Abstract\)](#page-3-0). In addition, the scFv was fused with alkaline phosphatase (scFv-AP) which could directly react with pNPP for colorimetric development without the use of secondary antibodies so that the detection process was simplified. At the same time, the scFv-AP can be expressed in *E. coli* on a large scale, which further reduces the cost.

# 2. Materials and methods

#### 2.1. Synthetic antibody library

The library used in this study was provided by BioNC [\(www.bionc.com.cn\)](http://www.bionc.com.cn), and it contained over  $3 \times 10^{10}$ human antibodies in the scFv format. The library was designed with the aim to obtain highly stable antibody clones, which were found to be highly functional, as ∼80% of randomly selected clones expressed the corresponding antibody.

#### 2.2. Biopanning

Biopanning of anti-SAL scFv from constructed phage-displayed scFv library was carried out according to standard protocols with some modifications [\(Barbas et al., 2001\)](#page-8-31). In brief, in the first round of biopanning, immunotubes were coated with 100µg/ml of SAL-BSA in carbonate coating buffer overnight at 4◦C and washed six times with PBST (PBS containing 0.1% Tween20). After being blocked with 5% skim milk for 1 h at 37°C and washed 10 times,  $\sim$ 10<sup>11</sup> pfu/ml recombinant phages were added into SAL-BSA coated immunotubes and incubated for 1 h at 37◦C with gentle shaking. The unbound phages were washed away with PBST 20 times. Then, the bound phages were eluted with elution buffer (0.2 M Glycine-HCl pH2.2) for 10 min at 37◦C and immediately neutralized with 1 M Tris– HCl (pH9). In total, 500 µl of log phase *E. coli* TG1 was added to tubes and reinfected at 37◦C for 1 h. The infected cells were plated on an LB agar plate containing  $100 \mu$ g/ml ampicillin and 2% glucose and incubated overnight at 37◦C. For the next three rounds of biopanning, in all cases, the number of inputted phages remained the same while the concentration of coated SAL-BSA/OVA/KLH was gradually reduced to 75, 50, and  $25 \mu g/ml$  in the second, third, and fourth rounds of biopanning, respectively.

# 2.3. Selection of recombinant phage antibody clones

Phage ELISA was carried out to identify phages that can specifically bind with SAL. In brief, microtitration plates (Corning) were coated with  $1 \mu g/ml$  SAL-BSA or BSA (negative control) and blocked with 5% skim milk. Phage solution diluted with equivalent blocking buffer was added to the plate and incubated for 1h at 37°C. After washing five times with PBST, 100 µl of HRP-conjugated anti-M13 antibody diluted 1:5,000 in PBST to detect bonded recombinant phage scFv was added and incubated for 1 h at 37◦C. After washing as mentioned above,  $100 \mu l$  of TMB was added to each well for colorimetric development, and the reaction was stopped with  $2 M H_2SO_4$ . The absorbance was determined at 450 nm with a microtiter plate reader (TECAN). Afterward, ELISA-positive phage clones were used for sequencing.

## 2.4. Competitive monoclonal phage ELISA

Competitive phage ELISA was performed to determine the specificity of the isolated phage-scFvs toward SAL. Selected clones with the highest apparent affinity were further characterized by multipoint competitive phage ELISA. Phages were normalized to 5  $\times$  10<sup>9</sup> cfu and challenged by incubation with SAL standards ranging from 0 to 10.0µg/ml in 5µg/ml SAL-BSA-coated microtitration plates in the first incubation step. Plates were washed with PBST three times and added with 1:5,000 HRP-conjugated anti-M13 antibody. Then, plates were washed with PBST three times, the colorimetric development was performed by the addition of TMB, the reaction stopped with  $2M H_2SO_4$ , and the absorbance was measured at 450 nm.

## 2.5. Construction of phage library with CDR randomization

Two libraries were constructed for sequential randomization of CDR-H3 and CDR-L3, using degenerated oligonucleotides with the NNS motif ( $N = A/C/G/T$  and  $S = C/G$ ) [\(Barbas et al., 2001\)](#page-8-31). The first library was constructed by mutating the five residues at CDR-H3 located at positions 99–103. The second library was prepared to randomize CDR-L3 residues 213–221 of the CDR-H3 mutant. The oligonucleotides were designed to permit any amino acid at each position while decreasing the presence of stop codons and cysteines. PCRs were performed by using the KOD polymerase (Takara).

## 2.6. Cloning, expression, and purification of anti-SAL scFv/scFv-AP

The selected scFv genes were amplified and ligated into pET-22b (+) and AP expression vector bAP (BioNC) by seamless cloning using a pEASY-Basic Seamless Cloning and Assembly kit (TransGen), according to the manufacturer's instructions. The ligated plasmids were heat-shocked and transformed into *E. coli* TG1 competent cells. Transformed cells were plated onto LB agar plates with  $100 \mu$ g/ml ampicillin and incubated overnight at 37◦C. Colony PCR was used to screen for positive clones harboring scFv inserts. Afterward, correct clones were used for sequencing. The sequenced plasmids were transformed into *E. coli* BL21(DE3) competent cells, which were grown in 100 ml LB medium containing 100µg/ml ampicillin with shaking at 37 $\mathrm{^{\circ}C}$ until the OD600 reached 0.8. Isopropyl-β-D-thiogalactopyranoside (IPTG) with a final concentration of 0.6 mM was added, and the bacteria were allowed to grow overnight at 25◦C with continuous shaking at 220 rpm. The cell pellets were harvested and thoroughly re-suspended in sonication buffer (20 mM Tris, 300 mM NaCl, pH 8.0), containing protease inhibitor (Sigma) and DNase I (Sango), according to the manufacturer's instructions. Then, the re-suspended cell pellets were lysed by sonication on the ice at 300W for 30 min (sonication for 4 s and intermission for 6 s) using a 6 mm diameter microtip (Scientz). The resulting suspension was centrifuged at 12,000 *g* for 30 min at 4◦C. The supernatant was



<span id="page-3-0"></span>then applied to a 5 ml Ni-Sepharose column equilibrated with buffer A (20 mM Tris, 300 mM NaCl, and 10 mM imidazole, pH 8.0). The column was washed first with buffer A and then with buffer B (20 mM Tris, 300 mM NaCl, and 20 mM imidazole, pH 8.0). Protein was eluted with Buffer C (20 mM Tris, 300 mM NaCl, and 200 mM imidazole, pH 8.0). Purified proteins were analyzed by SDS–PAGE.

#### 2.7. ELISA for measuring the binding of scFv and scFv-AP with SAL

ELISA was performed to measure the binding of the expressed scFv and scFv-AP with SAL. Each well of the microtitration plates (Corning) was coated with 100  $\upmu$ l of 1 $\upmu$ g/ml SAL-BSA in PBS and incubated for 1 h at 37 $\degree$ C followed by blocking with 200 µl of 5% skim milk for 1 h at 37°C. A total of 100 µl purified scFv or scFv-AP, which has been mixed with various concentrations of free SAL for 1 h was added to the plate and incubated for another 1 h at 37◦C. For the scFv added wells, after washing with PBST, 100  $\mu$ l of 1:5,000 diluted HRP-conjugated Anti-His Tag antibody (BioNC) was added to 5% skim milk, and the plate was incubated for 1 h at 37◦C. After a second wash with PBST, 100  $\mu$ l of TMB was added, and the OD was measured at 450 nm. Meanwhile, for the scFv-AP added wells, after washing with PBST, 100  $\mu$ l of pNPP was added, and the OD was measured at 405 nm.

#### 2.8. Homology modeling and SAL docking

The 3D structure of 4D6 scFv was predicted by Robetta with default parameters [\(https://robetta.bakerlab.org/\)](https://robetta.bakerlab.org/). AutoDock Vina is used as a docking tool to explore the binding of SAL with 4D6 [\(Trott and Olson, 2010\)](#page-8-32). The built model of 4D6 is used as a receptor and prepared by MGLTools to add hydrogens and Kollman charge. The docking box center is set to the geometric center of CDR loops, and the box size is set to  $28 \times 28 \times 8$  Å, containing the entire CDR domains. The three-dimensional structure of SAL in the sdf format is downloaded from PubChem [\(https://pubchem.ncbi.nlm.nih.gov/](https://pubchem.ncbi.nlm.nih.gov/compound/Salbutamol) [compound/Salbutamol\)](https://pubchem.ncbi.nlm.nih.gov/compound/Salbutamol) and OpenBabel [\(O'Boyle et al., 2011\)](#page-8-33) and is used to convert it into a mol2 file. The MGLTools are used to generate the ligand pdbqt file with Gasteiger charge added and flexible bond set as default. The Vina was used to dock SAL to 4D6 with all the other parameters set as defaults.

# 3. Results

#### 3.1. Phage displaying of ScFv antibody, biopanning, and screening

The library glycerol stock was inoculated into the LB medium and grown at 37◦C. In the presence of helper phage M13KO7, the scFv fusion protein was displayed on the surface of the recombinant phage, allowing for biopanning and affinity screening. A biopanning strategy was devised in which the SAL carrier protein conjugates would be different for each panning round. The aim of the panning strategy was to reduce scFvs which bound the carrier protein rather than SAL itself. SAL-BSA was used in the first and last rounds of panning, while SAL-OVA and SAL-KLH were used in the second and third rounds, respectively. SAL-BSA-specific phages were obtained after the fourth panning round and showed no binding toward any of the irrelevant carrier proteins based on the polyclonal phage ELISA results [\(Figure 1A\)](#page-4-0). To further discern which of these clones were specific to SAL alone, competitive monoclonal phage ELISA was carried out. From this experiment, three clones from the fourth panning round were found to be specific to SAL [\(Figure 1B\)](#page-4-0). Sequencing results showed that they contained different scFv fragments. Since clone 4D6 exhibited the highest affinity with SAL, it was chosen for the next improvement by affinity maturation.

#### 3.2. Interactive docking of SAL to 4D6

The 4D6-SAL complex model was predicted by AutoDock vina with the standard docking protocol. Amino acids are numbered sequentially. A total of 10 poses are generated with docking scores ranging from −5.961 to −5.362 kcal/mol. For the top one docking pose, SAL bound between the H chain and L chain, forming



<span id="page-4-0"></span>contacts with residues from CDR loops [\(Figure 2A\)](#page-5-0). Hydrogen bonds were observed between the hydroxyl groups of SAL and side chains of ASN35, GLU158, and TYR173 [\(Figure 2B\)](#page-5-0). Otherwise, SAL formed interactions with TYR33 from CDR-H1; TRP47 from FR-H2; ASP50 from CDR-H2 and GLN99; SER100 from CDR-H3; TYR156 and LYS174 from FR-L2; PHE213, SER216, VAL218, and PHE220 from CDR-L3. In this model, HCDR3 and LCDR3 of the 4D6 scFv appeared to contribute mainly to antigen binding.

# 3.3. CDR-H3 and CDR-L3 affinity maturation by random mutagenesis

The CDR-H3 and CDR-L3 affinity maturation of 4D6 scFv was performed by *in vitro* evolution. The use of degenerated oligonucleotides reduces the number of oligonucleotides and introduces a natural evolution in the process [\(Yang et al., 1995\)](#page-9-2). According to the docking results, the four amino acids between



<span id="page-5-0"></span>positions 99–103 in CDR-H3 were selected to randomize by using a phage scFv library of  $1 \times 10^6$  transformants. Two scFvs, 4D6H1 and 4D6H2, with improved recognition of SAL by ELISA, were obtained after three rounds of panning. Analysis by ELISA showed that the efficiency of 4D6H1 and 4D6H2 was 0.066 and 0.23µg/ml, having ∼seven-fold and ∼two-fold improvement with respect to the parental 4D6 scFv (0.43  $\mu$ g/ml), respectively [\(Figure 3](#page-6-0) and [Table 1\)](#page-5-1). The most improved variant (4D6H1) presented two amino acid mutations (T101S and F103Y; [Table 1\)](#page-5-1). For the 4D6H2 scFv, we observed three different mutations (T101A, G102D, and F103T).

4D6H1 scFv was selected to initiate the second round of maturation based on CDR-L3 mutagenesis. Based on the docking results, a new library was created by randomization of the four amino acids located at positions 213–221. The resulting phage library contained  $1.5 \times 10^6$  different transformants. Two scFvs, 4D6H1L1 and 4D6H1L2, were obtained after three rounds of panning. It is shown that 4D6H1L2 had mostly efficient recognition of SAL with  $IC_{50}$  of 0.017  $\mu$ g/ml, approximately a four-fold improvement to 4D6H1 [\(Figure 4\)](#page-6-1). The amino acid mutations are presented in [Table 1.](#page-5-1)

## 3.4. Soluble scFv/scFv-AP expression and analysis

4D6H1L2 scFv gene fragment was seamlessly cloned into the pET-22b (+) vector and the AP expression vector bAP. Then, the correctly sequenced recombinant plasmid was transformed into BL21 (DE3). After IPTG induction, the scFv and scFv-AP were purified through Ni-NTA affinity chromatography. The size and purity of scFv were verified on SDS–PAGE gel with one major band shown at MW ∼25 kD. Meanwhile, the scFv-AP fusion protein showed one dominant band with an expected size of ∼75 kD by SDS–PAGE [\(Figure 5\)](#page-7-0). The binding activity of 4D6H1L2 scFv-AP to SAL was evaluated in competitive ELISA (Figure 6). The scFv-AP



<span id="page-5-1"></span>∗The efficiency increase is a relative value to 4D6. The bold letters indicate the mutated residues. mutated residues. the. The bold letters indicate 4D6. efficiency increase is a relative value to

TABLE 1 Mutations of anti-SAL clones derived from the random CDR-H3 and CDR-L3 libraries



<span id="page-6-0"></span>can serve as a bifunctional immunoreagent integrating recognition of SAL with high enzymatic activity. The  $IC_{50}$  value of the scFv-AP for SAL is  $0.010 \mu g/ml$ , comparable to  $4D6H1L2$  scFv alone,  $0.017 \,\mathrm{\upmu}\mathrm{g/mL}$  It is indicated that the fusion protein keeps the same or even a little bit better ability to recognize SAL in the assays. Otherwise, the dimerization of the fusion protein might improve the binding avidity of scFv, further giving rise to the improvement of sensitivity to SAL [\(Kortt et al., 2001;](#page-8-34) [Liu et al., 2013\)](#page-8-35).

# 4. Discussion

Antibodies are still important molecular probes for detecting β2 agonists in biological and environmental matrices. There have been many studies using phage display technology to produce specific antibodies against various antigens. In this study, specific anti-SAL scFvs were screened from a synthetic antibody library. It is important to perform panning with blocking reagents before positive selection, which will significantly reduce the number of non-specific phages. Meanwhile, switching the carrier protein between each panning round reduces the presentation frequency of non-specific motifs of the carrier protein itself.

Clone 4D6 showed the strongest binding affinity based on phage ELISA [\(Figure 1B\)](#page-4-0), hence, we performed a stepwise *in vitro* affinity maturation procedure to improve the affinity of 4D6. We obtained a 3D model of the 4D6-SAL complex to identify the amino acids in the CDRs that needed to be mutated. In this model, CDR-H3 and CDR-L3 seemed to be involved in SAL binding. The heavy chain is considered to contribute to antigen binding to a greater extent than the light chain, especially through the CDR-H3 [\(Chothia and Lesk, 1987\)](#page-8-36). Therefore, mutagenesis in the CDR-H3 was attempted first. We identified two clones, 4D6H1, which had a seven-fold increased affinity, and 4D6H2, which had a two-fold increased affinity. The differences in the affinities of 4D6H1 and 4D6H2 might be caused by the changes in different



<span id="page-6-1"></span>amino acids. The mutations introduced in 4D6H1 might have contributed to the better positioning of the residues for tighter binding to SAL than the mutations in 4D6H2. Then, we performed randomization of the CDR-L3 using 4D6H1 as the template. Two clones, 4D6H1L1 and 4D6H1L2, were identified from the CDR-L3 randomized library, with an ∼25-fold improvement compared to the parental clone 4D6. This phenomenon was consistent with numerous structural and functional studies, which have shown that HCDR3 usually plays a dominant role in antigen binding (Xu and Davis, [2000;](#page-8-37) [Martinez et al., 2007;](#page-8-38) [Schoonbroodt et al., 2008\)](#page-8-39). Finally, we selected 4D6H1L2 for further characterization because of its highest binding affinity.

The level of sensitivity of the immunoassay depends on a number of factors, especially the affinity of detecting antibodies and the enzyme used. Varieties of enzymes are used as markers in immunoassays, and the most commonly conjugated enzymes are horseradish peroxidase, alkaline phosphatase, β-galactosidase, and glucoamylase [\(Wild, 2013\)](#page-8-40). AP is frequently used due to its number of advantages, such as its high catalytic activity, good enzymatic stability, high affinity and high turnover for a large range of substrates, and easy conjugation to antibodies in a cost-efficient way [\(Chen et al., 2018\)](#page-8-41).



<span id="page-7-0"></span>Here, we choose AP to develop a fusion protein with the scFv 4D6H1L2, with the aim to detect SAL by one-step ELISA. Traditional ELISAs for SAL are commonly performed in a two-step competitive protocol consisting of a primary antibody and a secondary antibody conjugated to HRP. Compared with traditional ELISAs, less immunoreagents and shorter time were required in the scFv-AP-based ELISA because the addition of a secondary antibody was avoided. It is shown that scFv-AP presents high efficiency to detect SAL in one-step ELISA, with IC<sub>50</sub> of 0.010  $\mu$ g/ml (Figure 6). Since the IC<sub>50</sub> value of salbutamol detected by  $4D6H1L2$  scFv was  $0.017 \mu g/ml$ , this indicates that the fusion of AP did not lead to a decrease in antibody affinity. In addition, the fusion protein could be easily produced and expressed in bacteria with a high yield which could reach 300 mg/L (data not shown). Furthermore, to the best of our knowledge, this study is the first to apply AP fusion scFv antibody for the detection of SAL. Moreover, the sensitivity of scFv-APbased ELISA is good enough to detect SAL in environmental matrices. The resulting assay showed great promise for rapid analysis of SAL in various samples, especially in the case of a large screening campaign, reducing the analysis time and the cost of analysis.

# 5. Conclusion

A novel scFv antibody (4D6) against the β2-agonist SAL from a synthetic antibody library was successfully isolated and characterized. Molecular docking is used to predict the complex structure of 4D6 and SAL. The model shows that residues on H3 and L3 contribute to the binding of SAL. Then, the CDR-H3 and CDR-L3 affinity maturation of 4D6 scFv was performed by *in vitro* evolution, and 4D6H1L2 was finally identified with high efficiency to detect SAL. The fusion protein is constructed by 4D6H1L2 and alkaline phosphatase, which is applied to one-step ELISA and showed good ability for SAL detection. The study may provide a new method for rapid analysis of SAL in various samples.

## Data availability statement

The original contributions presented in the study are included in the article[/Supplementary material,](#page-7-1) further inquiries can be directed to the corresponding authors.

# Author contributions

SH, GY, SC, ML, and RK: conceptualization. SH, GY, and RK: methodology. SH, DZ, SC, and RK: software. SH, GY, ZC, BL, and RK: formal analysis and writing—original draft preparation. SH, GY, BL, ML, QL, DZ, SC, and RK: investigation. ML, ZC, and SC: resources. SH, GY, DZ, QL, and RK: data curation. SH, GY, ZC, ML, QL, and SC: writing reviewing and editing. SC, ML, and RK: supervision. All authors have read and agreed to the published version of the manuscript.

# Funding

This study was supported by the National Natural Science Foundation of China (81603152) and the Changzhou Sci. and Tech. Program (CE20205033).

# Acknowledgments

We thank Primary Biotechnology [\(www.pumeirui.com\)](http://www.pumeirui.com) for the help on the modeling work.

# Conflict of interest

BL and ML were employed by Beijing New BioConcepts Biotech Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

#### Supplementary material

<span id="page-7-1"></span>The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fmicb.2023.](https://www.frontiersin.org/articles/10.3389/fmicb.2023.1190793/full#supplementary-material) 1190793/full#supplementary-material

#### References

<span id="page-8-28"></span>Adam, A., Ong, H., Sondag, D., Rapaille, A., Marleau, S., Bellemare, M., et al. (1990). Radioimmunoassay for albuterol using a monoclonal antibody: application for direct quantification in horse urine. *J. Immunoassay* 11, 329–345. doi: [10.1080/01971529008055036](https://doi.org/10.1080/01971529008055036)

<span id="page-8-1"></span>Baker, P. K., Dalrymple, R. H., Ingle, D. L., and Ricks, C. A. (1984). Use of a β-adrenergic agonist to alter muscle and fat deposition in lambs. *J. Anim. Sci*. 59, 1256–1261. doi: [10.2527/jas1984.5951256x](https://doi.org/10.2527/jas1984.5951256x)

<span id="page-8-31"></span>Barbas, C. F., Burton, D. R., Scott, J. K., and Silverman, G. J. (2001). *Phage Display: A Laboratory Manual*. New York, NY: Cold Spring Harbor Laboratory Press.

<span id="page-8-15"></span>Black, S. B., and Hansson, R. C. (1999). Determination of salbutamol and detection of other beta agonists in human postmortem whole blood and urine by GC-MS-SIM. *J. Anal. Toxicol*. 23, 113–118. doi: [10.1093/jat/23.2.113](https://doi.org/10.1093/jat/23.2.113)

<span id="page-8-13"></span>Bound, J. P., and Voulvoulis, N. (2006). Predicted and measured concentrations for selected pharmaceuticals in UK rivers: implications for risk assessment. *Water Res*. 40, 2885–2892. doi: [10.1016/j.watres.2006.05.036](https://doi.org/10.1016/j.watres.2006.05.036)

<span id="page-8-21"></span>Cai, F. D., Wang, N., Dong, T. T., Deng, A. P., and Li, J. G. (2015). Dual-signal amplified electrochemiluminescence immunoassay for salbutamol based on quantum dots and gold nanoparticle-labeled horseradish peroxidase. *Analyst* 140, 5885–5890. doi: [10.1039/C5AN00999E](https://doi.org/10.1039/C5AN00999E)

<span id="page-8-41"></span>Chen, C., Zhao, J., Lu, Y., Sun, J., and Yang, X. (2018). Fluorescence immunoassay based on the phosphate-triggered fluorescence turn-on detection of alkaline phosphatase. *Anal. Chem*. 90, 3505–3511. doi: [10.1021/acs.analchem.7b05325](https://doi.org/10.1021/acs.analchem.7b05325)

<span id="page-8-36"></span>Chothia, C., and Lesk, A. M. (1987). Canonical structures for the hypervariable regions of immunoglobulins. *J. Mol. Biol*. 196, 901–917. doi: [10.1016/0022-2836\(87\)90412-8](https://doi.org/10.1016/0022-2836(87)90412-8)

<span id="page-8-2"></span>Dalrymple, R. H., Baker, P. K., Gingher, P. E., Ingle, D. L., Pensack, J. M., Ricks, C. A., et al. (1984). A repartitioning agent to improve performance and carcass composition of broilers. *Poult. Sci.* 63, 2376–2383. doi: [10.3382/ps.0632376](https://doi.org/10.3382/ps.0632376)

<span id="page-8-18"></span>Degand, G., Bernes-Duyckaerts, A., Delahaut, P., and Maghuin-Rogister, G. (1993). Determination of β-agonists in urine by an enzyme immunoassay based on the use of an anti-salbutamol antiserum. *Anal. Chim. Acta*. 275, 241–247. doi: [10.1016/0003-2670\(93\)80298-Y](https://doi.org/10.1016/0003-2670(93)80298-Y)

<span id="page-8-11"></span>Depaolini, A. R., Fattore, E., Cappelli, F., Pellegrino, R., Castiglioni, S., Zuccato, E., et al. (2016). Source discrimination of drug residues in wastewater: the case of salbutamol. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci*. 1023–1024, 62–67. doi: [10.1016/j.jchromb.2016.04.033](https://doi.org/10.1016/j.jchromb.2016.04.033)

<span id="page-8-10"></span>Fang, S., Zhang, Y. Z., Liu, X., Qiu, J., Liu, Z. J., Kong, F. Y., et al. (2019). Development of a highly sensitive time-resolved fluoroimmunoassay for the determination of trace salbutamol in environmental samples. *Sci. Total Environ.* 679, 359–364. doi: [10.1016/j.scitotenv.2019.05.057](https://doi.org/10.1016/j.scitotenv.2019.05.057)

<span id="page-8-8"></span>Garssen, G. J., Geesink, G. H., Hoving-Bolink, A. H., and Verplanke, J. C. (1995). Effects of dietary clenbuterol and salbutamol on meat quality in veal calves. *Meat Sci*. 40, 337–50. doi: [10.1016/0309-1740\(94\)00034-5](https://doi.org/10.1016/0309-1740(94)00034-5)

<span id="page-8-26"></span>Gu, C. X., Ren, P. F., Zhang, F., Zhao, G. Z., Shen, J., Zhao, B., et al. (2020). Detection of six β-agonists by three multiresidue immunosensors based on an antibovine serum albumin-ractopamine-clenbuterol-salbutamol antibody. *ACS Omega* 5, 5548–5555. doi: [10.1021/acsomega.0c00249](https://doi.org/10.1021/acsomega.0c00249)

<span id="page-8-3"></span>Jones, R. W., Easter, R. A., McKelth, F. K., Dalrymple, R. H., Maddock, H. M., Bechtel, P. J., et al. (1985). Effect of the β-adrenergic agonist cimaterol (CL 263,780) on the growth and carcass characteristics of finishing swine. *J. Anim. Sci*. 61, 905–913. doi: [10.2527/jas1985.614905x](https://doi.org/10.2527/jas1985.614905x)

<span id="page-8-7"></span>Kearns, C. F., McKeever, K. H., Malinowski, K., Struck, M. B., and Abe, T. (1985). (2001). Chronic administration of therapeutic levels of clenbuterol acts as a repartitioning agent. *J. Appl. Physiol.* 91, 2064–2070. doi: [10.1152/jappl.2001.91.5.2064](https://doi.org/10.1152/jappl.2001.91.5.2064)

<span id="page-8-5"></span>Khamta, Y., Pattarawarapan, M., Nangola, S., and Tayapiwatana, C. (2009). Development of immunochromatographic assay for the on-site detection of salbutamol. *J. Immunoassay Immunochem*. 30, 441–456. doi: [10.1080/15321810903188284](https://doi.org/10.1080/15321810903188284)

<span id="page-8-34"></span>Kortt, A. A., Dolezal, O., Power, B. E., and Hudson, P. J. (2001). Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. *Biomol. Eng*. 18, 95–108. doi: [10.1016/S1389-0344\(01\)00090-9](https://doi.org/10.1016/S1389-0344(01)00090-9)

<span id="page-8-30"></span>Lee, W., Ali Syed, A., Leow, C. Y., Tan, S. C., and Leow, C. H. (2018). Isolation and characterization of a novel anti-salbutamol chicken scFv for human doping urinalysis. *Anal. Biochem*. 555, 81–93. doi: [10.1016/j.ab.2018.05.009](https://doi.org/10.1016/j.ab.2018.05.009)

<span id="page-8-19"></span>Lei, Y. C., Tsai, Y. F., Tai, Y. T., Lin, C. Y., Hsieh, K. H., Chang, T. H., et al. (2008). Development and fast screening of salbutamol residues in swine serum by an enzyme-linked immunosorbent assay in Taiwan. *J. Agric. Food Chem*. 56, 5494–5499. doi: [10.1021/jf800625f](https://doi.org/10.1021/jf800625f)

<span id="page-8-12"></span>Lei, Y. J., Li, X. Y., Muhammad, S. H. A., Zhou, L. F., Tang, X. J., Shi, W. X., et al. (2015a). Development of analytical method for ultrasensitive detection of salbutamol utilizing DNA labeled-immunoprobe. *J. Pharm. Biomed. Anal.* 107, 204–208. doi: [10.1016/j.jpba.2014.12.027](https://doi.org/10.1016/j.jpba.2014.12.027)

<span id="page-8-20"></span>Lei, Y. J., Yao, X. Y., Zhang, D., Zhou, L. F., Lu, W. X., Chen, S. Q., et al. (2015b). Investigation of the salbutamol residue level in human urinary samples by a sensitive direct competitive ELISA. *Anal. Methods* 7, 5635–5640. doi: [10.1039/C5AY00544B](https://doi.org/10.1039/C5AY00544B)

<span id="page-8-25"></span>Li, M., Zhang, Y. Y., Xue, Y. L., Hong, X., Cui, Y., Liu, Z. J., et al. (2017). Simultaneous determination of β2-agonists clenbuterol and salbutamol in water and swine feed samples by dual-labeled time-resolved fluoroimmunoassay. *Food Control*. 73, 1039–1044. doi: [10.1016/j.foodcont.2016.10.019](https://doi.org/10.1016/j.foodcont.2016.10.019)

<span id="page-8-24"></span>Liu, B., Wang, L. L., Tong, B., Zhang, Y., Sheng, W., Pan, M. F., et al. (2016). Development and comparison of immunochromatographic strips with three nanomaterial labels: colloidal gold, nanogold-polyaniline-nanogold microspheres (GPGs) and colloidal carbon for visual detection of salbutamol. *Biosens. Bioelectron*. 85, 337–342. doi: [10.1016/j.bios.2016.05.032](https://doi.org/10.1016/j.bios.2016.05.032)

<span id="page-8-35"></span>Liu, J. L., Zabetakis, D., Lee, A. B., Goldman, E. R., and Anderson, G. P. (2013). Single domain antibody-alkaline phosphatase fusion proteins for antigen detectionanalysis of affinity and thermal stability of single domain antibody. *J. Immunol. Methods* 393, 1–7. doi: [10.1016/j.jim.2013.04.001](https://doi.org/10.1016/j.jim.2013.04.001)

<span id="page-8-14"></span>Liu, Z., Zhang, B., Sun, J., Yi, Y., Li, M., Du, D., et al. (2018). Highly efficient detection of salbutamol in environmental water samples by an enzyme immunoassay. *Sci Total Environ*. 613–614, 861–865. doi: [10.1016/j.scitotenv.2017.08.324](https://doi.org/10.1016/j.scitotenv.2017.08.324)

<span id="page-8-17"></span>Liu, Z. J., Wei, X., Ren, K. W., Zhu, G. B., Zhang, Z., Wang, J. G., et al. (2016). Highly efficient detection of paclobutrazol in environmental water and soil samples by timeresolved fluoroimmunoassay. *Sci. Total Environ*. 569–570, 1629–1634. doi: [10.1016/j.scitotenv.2016.06.089](https://doi.org/10.1016/j.scitotenv.2016.06.089)

<span id="page-8-38"></span>Martinez, O., Gangi, E., Mordi, D., Gupta, S., Dorevitch, S., Lefranc, M. P., et al. (2007). Diversity in the complementarity-determining region 3 (CDR3) of antibodies from mice with evolving anti-thyroid-stimulating hormone receptor antibody responses. *Endocrinology* 148, 752–761. doi: [10.1210/en.2006-1096](https://doi.org/10.1210/en.2006-1096)

<span id="page-8-33"></span>O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., Hutchison, G. R., et al. (2011). Open babel: an open chemical toolbox. *J. Cheminform*. 3, 33. doi: [10.1186/1758-2946-3-33](https://doi.org/10.1186/1758-2946-3-33)

<span id="page-8-0"></span>Price, A. H., and Clissold, S. P. (1989). Salbutamol in the 1980s: a reappraisal of its clinical efficacy. *Drugs*. 38, 77–122. doi: [10.2165/00003495-198938010-00004](https://doi.org/10.2165/00003495-198938010-00004)

<span id="page-8-16"></span>Rosales-Conrado, N., Dell'Aica, M., León-González, M. E. D., Pérez-Arribas, L.V., and Polo-Díez, L. M. (2013). Determination of salbutamol by direct chiral reversedphase HPLC using teicoplanin as stationary phase and its application to natural water analysis. *Biomed. Chromatogr*. 27, 1413–1422. doi: [10.1002/bmc.2937](https://doi.org/10.1002/bmc.2937)

<span id="page-8-39"></span>Schoonbroodt, S., Steukers, M., Viswanathan, M., Frans, N., Timmermans, M., Wehnert, A., et al. (2008). Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates. *J. Immunol*. 181, 6213–6221. doi: [10.4049/jimmunol.181.9.6213](https://doi.org/10.4049/jimmunol.181.9.6213)

<span id="page-8-6"></span>Sheu, S. Y., Lei, Y. C., Tai, Y. T., Chang, T. H., and Kuo, T. F. (2009). Screening of salbutamol residues in swine meat and animal feed by an enzyme immunoassay in Taiwan. *Anal. Chim. Acta.* 654, 148–153. doi: [10.1016/j.aca.2009.09.026](https://doi.org/10.1016/j.aca.2009.09.026)

<span id="page-8-32"></span>Trott, O., and Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem*. 31, 455–461. doi: [10.1002/jcc.21334](https://doi.org/10.1002/jcc.21334)

<span id="page-8-4"></span>Wang, J. P., and Shen, J. Z. (2007). Immunoaffinity chromatography for purification of salbutamol and clenbuterol followed screening and confirmation by ELISA and GC-MS. *Food Agric. Immunol*. 18, 107–115. doi: [10.1080/09540100701596609](https://doi.org/10.1080/09540100701596609)

<span id="page-8-9"></span>Wang, M. Y., Zhu, W., Ma, L., Ma, J. J., Zhang, D. E., Tong, Z. W., et al. (2015). (2016). Enhanced simultaneous detection of ractopamine and salbutamol– via electrochemical-facial deposition of MnO2 nanoflowers onto 3D RGO/Ni foam templates. *Biosens Bioelectron*. 78, 259–266. doi: [10.1016/j.bios.2015.11.062](https://doi.org/10.1016/j.bios.2015.11.062)

<span id="page-8-40"></span>Wild, D. (2013). *The Immunoassay Handbook: Theory and Applications of Ligand Binding, ELISA and Related Techniques*. 4th ed. Amsterdam: Elsevier Science Press.

<span id="page-8-27"></span>Wu, Y. P., Xu, F., Jiang, H. Y., Tao, X. Q., Zhu, K., Liu, W. L., et al. (2014). Determination of salbutamol, clenbuterol, and brombuterol in urine by a highly sensitive chemiluminescence enzyme immunoassay. *Anal. Lett*. 47, 2761–2773. doi: [10.1080/00032719.2014.917422](https://doi.org/10.1080/00032719.2014.917422)

<span id="page-8-29"></span>Xie, C. H., Chen, F. J., and Yang, T. B. (2012). A high-affinity anti-salbutamol monoclonal antibody: key to a robust lateral-flow immunochromatographic assay. *Anal. Biochem*. 426, 118–125. doi: [10.1016/j.ab.2012.04.015](https://doi.org/10.1016/j.ab.2012.04.015)

<span id="page-8-37"></span>Xu, J. L., and Davis, M. M. (2000). Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. *Immunity* 13, 37–45. doi: [10.1016/S1074-7613\(00\)00006-6](https://doi.org/10.1016/S1074-7613(00)00006-6)

<span id="page-8-22"></span>Xu, M. X., Qian, X. L., Zhao, K., Deng, A. P., and Li, J. G. (2015). Flow injection chemiluminescent competitive immunoassay for the β-adrenergic agonist salbutamol using carboxylic resin beads and enzymatic amplification. *Sens. Actuators B Chem*. 215, 323–329. doi: [10.1016/j.snb.2015.04.001](https://doi.org/10.1016/j.snb.2015.04.001)

<span id="page-8-23"></span>Xu, X., Xu, X., Sun, L., Wu, A., Song, S., Kuang, H., and Xu, C.. (2022). An ultrasensitive colloidal gold immunosensor to simultaneously detect 12 beta (2) adrenergic agonists. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 1191, 123119. doi: [10.1016/j.jchromb.2022.123119](https://doi.org/10.1016/j.jchromb.2022.123119)

<span id="page-9-0"></span>Yamini, Y., Reimann, C. T., Vatanara, A., and Jonsson, J. A. (2006). Extraction and preconcentration of salbutamol and terbutaline from aqueous samples using hollow fiber supported liquid membrane containing anionic carrier. *J. Chromatogr. A*. 1124, 57–67. doi: [10.1016/j.chroma.2006.05.001](https://doi.org/10.1016/j.chroma.2006.05.001)

<span id="page-9-2"></span>Yang, W. P., Green, K., Pinz-Sweeney, S., Briones, A. T., and Burton, D. R. Barbas 3rd CF. (1995). CDR walking mutagenesis for the affinity maturation of a potent

human anti-HIV-1 antibody into the picomolar range. *J. Mol. Biol*. 254, 392–403. doi: [10.1006/jmbi.1995.0626](https://doi.org/10.1006/jmbi.1995.0626)

<span id="page-9-1"></span>Zhang, D. J., Teng, Y. N., Chen, K. G., Liu, S., Wei, C. M., Wang, B. J., et al. (2012). Determination of salbutamol in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry and its pharmacokinetic study. *Biomed. Chromatogr*. 26, 1176–1182. doi: [10.1002/bmc.2675](https://doi.org/10.1002/bmc.2675)